-
Thousands of Chinese used a compound called maxingshigan-yinqiaosan (MY) for treatment of flu symptoms during the 2009 H1N1 epidemic. MY is a concoction of 12 different herbs, including toasted Herba ephedra, as well as qinghao, gypsum fibrosum, and rhizoma.
-
The SELECT Trial investigators report on nearly 10 years of follow-up of participants in a study of selenium and vitamin E and the risk of prostate cancer. A small but statistically significant increased risk of prostate cancer appears to be associated with taking vitamin E supplements. These results are in disagreement with others in the literature, and the authors present no plausible biological explanation for them. Nonetheless, the balance of evidence does not appear to support any recommendation that physicians advise their middle-aged and elderly patients to begin vitamin E supplementation for prostate cancer prevention.
-
A well-done meta-analysis showed that green tea, either as a beverage or as a supplement, could help lower total and LDL cholesterol levels in a statistically significant manner, but has no effect on HDL. The degree of clinical impact is debatable; what is not debatable is the poor quality of most studies on green tea and cholesterol.
-
In this issue: New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions.
-
This article reports findings of a task force set up by the Society of Critical Care Medicine in 2008 to study intensivist workforce issues in the face of the ongoing increase in ICU beds and numbers of critically ill patients.
-
-
-
Miller and colleagues conducted a survey of daily interruption of sedation (DIS) in U.S. hospitals and sought to determine whether organizational features were associated with DIS use. The survey was mailed to a stratified random sample of non-federal U.S. acute-care hospitals with more than 50 beds.
-
This paper gives the results of a substudy from the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial.
-
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an uncommon condition with a wide spectrum of possible clinical presentations. Implantable defibrillators (ICDs) are standard therapy for treating ARVD/C patients who present with sustained ventricular tachycardia (VT) or cardiac arrest.